Phase II Clinical Study of JTE-052 - Dose finding study in patients with atopic dermatitis -

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222835

Enrollment

300

Registered

2015-04-28

Start date

2015-05-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

investigational material(s) Generic name etc : JTE-052A INN of investigational material : delgocitinib Therapeutic category code : 269 Other agents for epidermis Dosage and Administration for Investi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - A historical diagnosis of moderate or severe atopic dermatitis - Modified Eczema Area and Severity Index (mEASI) >= 10

Exclusion criteria

Exclusion criteria: Patients with active infection at the study drug application site Use of topical corticosteroids (strongest or very strong) within 28 days before baseline Use of topical corticosteroids (strong, medium or weak) within 7 days before baseline

Design outcomes

Primary

Measure	Time frame
efficacy Percent change in mEASI	—

Secondary

Measure	Time frame
efficacy EASI IGA (Investigator's Global Assessment) Face and neck IGA NRS (Numeric Rating Scale) Percent body surface area (%BSA) affected by eczema with inflammation	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026